7-55191792-C-T

Variant summary

Our verdict is Likely benign. Variant got -3 ACMG points: 2P and 5B. PM2BP6BS1

The NM_005228.5(EGFR):​c.2543C>T​(p.Pro848Leu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000373 in 1,613,922 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.00026 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00039 ( 0 hom. )

Consequence

EGFR
NM_005228.5 missense

Scores

4
11
4

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:4B:4O:1

Conservation

PhyloP100: 7.85
Variant links:
Genes affected
EGFR (HGNC:3236): (epidermal growth factor receptor) The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor, thus inducing receptor dimerization and tyrosine autophosphorylation leading to cell proliferation. Mutations in this gene are associated with lung cancer. EGFR is a component of the cytokine storm which contributes to a severe form of Coronavirus Disease 2019 (COVID-19) resulting from infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). [provided by RefSeq, Jul 2020]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_benign. Variant got -3 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
BP6
Variant 7-55191792-C-T is Benign according to our data. Variant chr7-55191792-C-T is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 45282.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=3, not_provided=1, Benign=1, Uncertain_significance=3}.
BS1
Variant frequency is greater than expected in population nfe. gnomad4 allele frequency = 0.000256 (39/152068) while in subpopulation NFE AF= 0.000485 (33/68034). AF 95% confidence interval is 0.000354. There are 0 homozygotes in gnomad4. There are 17 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
EGFRNM_005228.5 linkuse as main transcriptc.2543C>T p.Pro848Leu missense_variant 21/28 ENST00000275493.7 NP_005219.2

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
EGFRENST00000275493.7 linkuse as main transcriptc.2543C>T p.Pro848Leu missense_variant 21/281 NM_005228.5 ENSP00000275493 P1P00533-1
EGFRENST00000455089.5 linkuse as main transcriptc.2408C>T p.Pro803Leu missense_variant 20/261 ENSP00000415559
EGFRENST00000450046.2 linkuse as main transcriptc.2384C>T p.Pro795Leu missense_variant 21/284 ENSP00000413354
EGFRENST00000700145.1 linkuse as main transcriptc.893C>T p.Pro298Leu missense_variant 8/9 ENSP00000514824

Frequencies

GnomAD3 genomes
AF:
0.000256
AC:
39
AN:
152068
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0000483
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000197
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.000194
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000485
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.000358
AC:
90
AN:
251310
Hom.:
0
AF XY:
0.000383
AC XY:
52
AN XY:
135816
show subpopulations
Gnomad AFR exome
AF:
0.0000616
Gnomad AMR exome
AF:
0.000173
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.0000544
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.000232
Gnomad NFE exome
AF:
0.000642
Gnomad OTH exome
AF:
0.000652
GnomAD4 exome
AF:
0.000385
AC:
563
AN:
1461854
Hom.:
0
Cov.:
31
AF XY:
0.000402
AC XY:
292
AN XY:
727228
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.000134
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.0000504
Gnomad4 SAS exome
AF:
0.0000116
Gnomad4 FIN exome
AF:
0.000300
Gnomad4 NFE exome
AF:
0.000466
Gnomad4 OTH exome
AF:
0.000331
GnomAD4 genome
AF:
0.000256
AC:
39
AN:
152068
Hom.:
0
Cov.:
32
AF XY:
0.000229
AC XY:
17
AN XY:
74266
show subpopulations
Gnomad4 AFR
AF:
0.0000483
Gnomad4 AMR
AF:
0.000197
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.000194
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.000485
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.000437
Hom.:
0
Bravo
AF:
0.000272
TwinsUK
AF:
0.000809
AC:
3
ALSPAC
AF:
0.000259
AC:
1
ESP6500AA
AF:
0.00
AC:
0
ESP6500EA
AF:
0.000698
AC:
6
ExAC
AF:
0.000461
AC:
56
EpiCase
AF:
0.000654
EpiControl
AF:
0.000356

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:4Benign:4Other:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitterclinical testingInstitute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU DresdenNov 03, 2021- -
Uncertain significance, criteria provided, single submitterclinical testingGeneDxMar 14, 2022In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Identified in the germline of individuals with lung cancer, glioma, and retinoblastoma (Sequist 2006, Prim 2014, Akhavanfard 2021); Published functional studies demonstrate reduced/absent auto-phosphorylation, kinase activity, and capacity to bind c-Cbl (de Gunst 2007, Sarcar 2019); This variant is associated with the following publications: (PMID: 22848293, 17877814, 25176975, 16857818, 33326033, 31314158) -
Benign, criteria provided, single submitterclinical testingQuest Diagnostics Nichols Institute San Juan CapistranoMay 01, 2023- -
not specified Uncertain:1Benign:1
Likely benign, criteria provided, single submitterclinical testingLaboratory for Molecular Medicine, Mass General Brigham Personalized MedicineJul 11, 2013Pro848Leu variant in Exon 21 of EGFR: This variant is not expected to have clinical significance because iIn vitro studies suggest that this variant does not activate EGFR activity and does not render the protein sensitive to tyrosine kinase inhibitors (TKIs) (De Gunst 2007, Han 2011). It has been previously identified in both tumor and normal tissue in an individuals with lung cancer (Sequist 2007), and it has been identified in 0.06% (6/8600) of European American chromosomes by the NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS/; dbSNP rs148934350). -
Uncertain significance, no assertion criteria providedclinical testingGenetic Services Laboratory, University of ChicagoJun 08, 2022DNA sequence analysis of the EGFR gene demonstrated a sequence change, c.2543C>T, in exon 21 that results in an amino acid change, p.Pro848Leu. This sequence change has been previously described in individuals with non-small cell lung cancer (NSCLC) (PMID: 25176975,16857818,22848293). In vitro functional studies have suggested that this variant is not a kinase activating mutation and showed a response to tyrosine kinase inhibitors, similar to the wild-type (PMID: 17877814, 22848293). This sequence change has been described in the gnomAD database with a frequency of 0.06% in the European subpopulation (dbSNP rs148934350). The p.Pro848Leu change affects a highly conserved amino acid residue located in a domain of the EGFR protein that is known to be functional. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Pro848Leu substitution. Due to insufficient evidences and the lack of functional studies, the clinical significance of the p.Pro848Leu change remains unknown at this time. -
Hereditary cancer-predisposing syndrome Uncertain:1
Uncertain significance, criteria provided, single submittercurationSema4, Sema4Nov 01, 2021- -
Lung carcinoma Benign:1
Likely benign, criteria provided, single submitterclinical testingMendelicsMay 28, 2019- -
EGFR-related lung cancer Benign:1
Likely benign, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpJan 18, 2024- -
Lung cancer Other:1
not provided, no classification providedphenotyping onlyGenomeConnect - Invitae Patient Insights Network-Variant interpreted as Uncertain significance and reported on 11-11-2019 by Lab Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.74
BayesDel_addAF
Benign
-0.067
T
BayesDel_noAF
Uncertain
0.030
CADD
Pathogenic
29
DANN
Uncertain
1.0
DEOGEN2
Uncertain
0.71
D;D;D
Eigen
Uncertain
0.50
Eigen_PC
Uncertain
0.47
FATHMM_MKL
Pathogenic
0.98
D
LIST_S2
Uncertain
0.95
D;D;D
M_CAP
Uncertain
0.14
D
MetaRNN
Uncertain
0.54
D;D;D
MetaSVM
Benign
-0.39
T
MutationAssessor
Benign
0.37
.;.;N
MutationTaster
Benign
1.0
D;D;D;D
PrimateAI
Pathogenic
0.89
D
PROVEAN
Pathogenic
-8.9
D;.;D
REVEL
Uncertain
0.47
Sift
Uncertain
0.0010
D;.;D
Sift4G
Uncertain
0.046
D;T;D
Polyphen
1.0
D;.;D
Vest4
0.73
MVP
0.84
MPC
1.5
ClinPred
0.22
T
GERP RS
5.8
Varity_R
0.95
gMVP
0.82

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs148934350; hg19: chr7-55259485; COSMIC: COSV51773049; COSMIC: COSV51773049; API